Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

Inclusion Criteria: * Male and female patients, aged 18 to 65 years inclusive, scheduled to undergo diagnostic upper GI endoscopy. * American Society of Anesthesiologists Physical Status (ASA PS) Score I or II. * Weight range 60 to 120 kg inclusive. * Body mass index (BMI) 18 to \< 30 kg/m2. * Patients with no clinically significant abnormalities in 12 lead ECG recorded at Screening. * Female with a negative serum human chorionic gonadotropin (hCG) pregnancy test result at Screening and negative urine hCG pregnancy test result on Day 1 before the endoscopy procedure. * Patients with negative drugs of abuse serum result at Screening and negative drugs of abuse urine result on Day 1 before the endoscopy procedure. * Patient has a negative serum ethanol test result at Screening and a negative ethanol saliva test result on Day 1 before the endoscopy procedure. * Patient voluntarily signs and dates an informed consent form (ICF) that is approved by an investigational review board (IRB) prior to the conduct of any study procedure. * Patient is willing and able to comply with study requirements and return for a Follow up Visit (Visit 3 ± 1 day) after the endoscopy procedure. Exclusion Criteria: * Patients with a suspected upper GI bleed an conditions predisposing to hemorrhage at the discretion of the investigator. * Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are contraindicated. * Patients with evid…